Compare Natera Inc. Common Stock (NTRA) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs WD 40 Company — how do they compare? Natera Inc. Common Stock trades at $392.78 (market cap $57.03B), while WD 40 Company trades at $205.55 (market cap $2.74B). The key difference: Natera Inc. Common Stock is far larger — about 20.8× WD 40 Company's market cap, and WD 40 Company pays a 2% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and WD 40 Company for 23 Days on average.
| NTRA | WDFC | |
|---|---|---|
Market Cap | $57.03B | $2.74B |
Volume | 1,131,157 | 123,545 |
Sector | Health | Basic Materials |
52-Week High | $425.64 | $264.91 |
52-Week Low | $179.42 | $187.52 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $56.18B | $2.80B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
WDFC trades at $204.41, up 0.8% today, with a bullish technical signal from moving averages and key resistance at $206. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.33, and maintains robust profitability with a 33.22% ROE. Recent news highlights strategic growth initiatives and institutional buying interest.
Outlook is mixed; solid fundamentals and growth strategy support upside, but high valuation (P/E 31.07) and margin pressures from input costs pose risks. Analyst consensus is cautious with 71% hold ratings, indicating tempered expectations despite operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
